A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
← catalyst calendarNCT06706622 · readout in 547 d
Sponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
401actual
Sites
74
Countries
Australia, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-03 | actual | When the study began enrolling |
| Primary completion | 2028-02-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple System Atrophy
Interventions
- Drug: Amlenetug — also filed as Lu AF82422
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFRest of the World (RoW; All Countries Except European Union [EU] and Japan [JP]) Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression
measured Baseline up to Week 72
EU and JP Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression
measured Baseline up to Week 72
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed